Ji’an Mankun’s Recent Performance and Market Context
Ji’an Mankun (301132.SZ) concluded the 24‑hour trading window at 06:16 AM Central Europe on Friday, 23 October with a flat 0 % change. The shares trade at approximately CNY 55.06 on major exchanges, with a circulating supply of 159.9 million shares and a market capitalization of CNY 9.7 billion. In the past 24 hours, roughly CNY 582.6 million of Ji’an Mankun shares have changed hands.
Key Technical Metrics
| Metric | Value |
|---|---|
| Current price | CNY 55.06 |
| 200‑day simple moving average | CNY 44.98 |
| 52‑week high | CNY 79.38 (15 Oct 2026) |
| 52‑week low | CNY 24.35 (21 Jul 2026) |
| 24‑hour volume | CNY 582.6 million |
| Market cap | CNY 9.7 billion |
Since the end of last month, Ji’an Mankun’s share price has declined by 19.07 %. The flat intraday performance indicates short‑term consolidation after a steep retreat. Given the recent swing from a 52‑week high of CNY 79.38 to its current level, the stock appears to be retrenching toward the 200‑day moving average, a potential support zone.
Comparative Performance of Peer Stocks
The immediate environment for Ji’an Mankun is marked by a broader sell‑off in the biotechnology and life‑sciences sector, as evidenced by the following peer performances over the last 24 hours:
| Stock | Ticker | 24‑hour change | Current price | Market cap | P/E ratio (if available) |
|---|---|---|---|---|---|
| Shenzhen Hepalink Pharmace | 9989.HK | –2.17 % | HKD 3.83 | HKD 13.5 bn | 24.15 |
| Nanjing Vazyme Biotech | 688105.SS | 0 % | CNY 20.05 | CNY 11.5 bn | – |
| Shuanglin | 300100.SZ | 0 % | CNY 19.17 | CNY 11.5 bn | 37.35 |
| Metis Techbio –H | 7666.HK | –7.83 % | HKD 10.14 | HKD 13.6 bn | – |
| Beijing Haizhi –H | 2706.HK | –10.01 % | HKD 28.30 | HKD 13.5 bn | – |
The peer group demonstrates a mixture of flat and negative moves, suggesting that the market’s sentiment toward biotechnology ventures remains cautious. Ji’an Mankun’s flat performance may reflect a temporary pause amid broader sectoral pressure, rather than a fundamental shift in its valuation.
Forward‑Looking Assessment
From a strategic standpoint, Ji’an Mankun’s current price sits well above the 200‑day simple moving average, implying that short‑term momentum has yet to fully materialise. If the stock can maintain levels near CNY 55, it could be positioned to break back above the 200‑day threshold, potentially unlocking a new upward trajectory.
Conversely, the significant decline from the 52‑week high and the ongoing negative trend since month‑end warrant vigilance. A failure to break through the 200‑day support zone could trigger a deeper correction, especially if the broader biotech sector continues its bearish drift.
Investors with a moderate risk tolerance might consider a scaled entry, targeting a price range between CNY 48 and CNY 52, to benefit from a potential rebound while mitigating downside exposure. Long‑term holders, on the other hand, should monitor the company’s quarterly earnings reports and product pipeline milestones, which could act as catalysts for a sustained rally.
This analysis synthesises current market data and peer performance to provide a concise, forward‑looking view of Ji’an Mankun’s position within the Chinese biotech sector.
